Skip to content
2000
Volume 22, Issue 3
  • ISSN: 1570-1638
  • E-ISSN: 1875-6220

Abstract

Background

Clopidogrel, an antiplatelet drug commonly used in cardiovascular disease, is metabolized by the liver mainly through CYP2C19. Concomitant use of Proton pump inhibitors along with clopidogrel may affect the potency of clopidogrel by CYP2C19 inhibition. However, a novel PPI, ilaprazole is known to differ in its pharmacokinetic features, given the potential differences between ilaprazole’s interactions and their metabolism with clopidogrel. Network pharmacology investigation could be a useful tool to evaluate the drug-drug interaction between them.

Methodology

The molecular structures and targets were retrieved from PubChem and SwissTargetPrediction to establish the information related to the identified drugs. The possible shared targets between the clopidogrel and PPIs were explored by a Venn analysis. Subsequently, Protein-Protein Interaction networks were established using the STRING database. Hub genes were also determined using the Cytoscape cytoHubba plugin.

Results and Discussion

Ilaprazole (13.6%) and pantoprazole (13.6%) were characterized by fewer targets being shared with clopidogrel compared to conventional PPIs (14.9%). Moreover, CYP2C19 was not a hub gene in ilaprazole and pantoprazole interactions, which indicated no significant CYP2C19 involvement. On the other hand, CYP2C19 functioned as a hub gene in the interactions with rabeprazole, lansoprazole, dexlansoprazole, omeprazole, and esomeprazole. As a result, patients receiving pantoprazole and ilaprazole would be at a lower risk for developing adverse cardiovascular events by maintaining the clopidogrel therapeutic effect.

Conclusion

The application of the network pharmacology technique allows us to consider the potential for different effects of PPIs on clopidogrel and its metabolism CYP2C19. There is a lower chance of experiencing adverse effects from an interaction between ilaprazole and clopidogrel as ilaprazole has not been linked to CYP2C19. More research is necessary to confirm these results and provide clinical guidance for patients undergoing clopidogrel and PPI combination therapy.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cddt/10.2174/0115701638334244241224062453
2024-12-31
2025-09-05

  • From This Site

    /content/journals/cddt/10.2174/0115701638334244241224062453
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SangkuhlK. KleinT.E. AltmanR.B. Clopidogrel pathway.Pharmacogenet. Genomics201020746346510.1097/FPC.0b013e3283385420 20440227
     [Google Scholar]
  2. RayW.A. MurrayK.T. GriffinM.R. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.Ann. Intern. Med.2010152633734510.7326/0003‑4819‑152‑6‑201003160‑00003 20231564
     [Google Scholar]
  3. DuttaA.K. JainA. JearthV. Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship.Indian J. Gastroenterol.202342560162810.1007/s12664‑023‑01428‑7 37698821
     [Google Scholar]
  4. DrepperM.D. SpahrL. FrossardJ.L. Clopidogrel and proton pump inhibitors where do we stand in 2012?World J. Gastroenterol.201218182161217110.3748/wjg.v18.i18.2161 22611308
     [Google Scholar]
  5. TantryU.S. KereiakesD.J. GurbelP.A. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations.JACC Cardiovasc. Interv.20114436538010.1016/j.jcin.2010.12.009 21511216
     [Google Scholar]
  6. JiangX.L. SamantS. LeskoL.J. SchmidtS. Clinical pharmacokinetics and pharmacodynamics of clopidogrel.Clin. Pharmacokinet.201554214716610.1007/s40262‑014‑0230‑6 25559342
     [Google Scholar]
  7. PolasekT.M. DoogueM.P. MinersJ.O. Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1.Ther. Adv. Drug Saf.20112625326110.1177/2042098611422559 25083217
     [Google Scholar]
  8. BouzianaS.D. TziomalosK. Clinical relevance of clopidogrel-proton pump inhibitors interaction.World J. Gastrointest. Pharmacol. Ther.201562172110.4292/wjgpt.v6.i2.17 25949846
     [Google Scholar]
  9. LiY. ZhangW. GuoD. ZhouG. ZhouH. XiaoZ. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.Clin. Chim. Acta20083911-2606710.1016/j.cca.2008.02.003 18319058
     [Google Scholar]
  10. LimI.H. LeeS.J. ShinB.S. KangH.G. Ilaprazole and clopidogrel resistance in acute stroke patients.Biomedicines2022106136610.3390/biomedicines10061366 35740386
     [Google Scholar]
  11. Alegría-ArcosM. BarbosaT. SepúlvedaF. Network pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19.Front. Pharmacol.20221395219210.3389/fphar.2022.952192 36052135
     [Google Scholar]
  12. WilsonJ.L. SteinbergE. RaczR. AltmanR.B. ShahN. GrimesK. A network paradigm predicts drug synergistic effects using downstream protein–protein interactions.CPT Pharmacometrics Syst. Pharmacol.202211111527153810.1002/psp4.12861 36204824
     [Google Scholar]
  13. DainaA. MichielinO. ZoeteV. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules.Nucleic Acids Res.201947W1W357-6410.1093/nar/gkz382 31106366
     [Google Scholar]
  14. HeberleH. MeirellesG.V. da SilvaF.R. TellesG.P. MinghimR. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams.BMC Bioinformatics201516116910.1186/s12859‑015‑0611‑3 25994840
     [Google Scholar]
  15. WuX. ZhengX. TangH. A network pharmacology approach to identify the mechanisms and molecular targets of curcumin against Alzheimer disease.Medicine (Baltimore)202210134e3019410.1097/MD.0000000000030194 36042609
     [Google Scholar]
  16. SzklarczykD. GableA.L. LyonD. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.Nucleic Acids Res.201947D1D607D61310.1093/nar/gky1131 30476243
     [Google Scholar]
  17. AkterT. RahmanM.M. Computational analysis of common gene and design protein-drug interaction network for the target diseases based on protein-protein interaction network in bioinformatics.Inform. Med. Unlocked20234210135710.1016/j.imu.2023.101357
     [Google Scholar]
  18. ChandranU. MehendaleN. PatilS. ChaguturuR. PatwardhanB. Network pharmacology.innovative approaches in drug discovery.Academic Press201712716410.1016/B978‑0‑12‑801814‑9.00005‑2
     [Google Scholar]
  19. Wahab KhattakF. Salamah AlhwaitiY. AliA. FaisalM. SiddiqiM.H. Protein-protein interaction analysis through network topology (oral cancer).J. Healthc. Eng.202120211910.1155/2021/6623904 33510888
     [Google Scholar]
  20. DmitrievA.V. RudikA.V. KarasevD.A. In silico prediction of drug-drug interactions mediated by cytochrome P450 isoforms.Pharmaceutics202113453810.3390/pharmaceutics13040538 33924315
     [Google Scholar]
  21. ChoH. ChoiM.K. ChoD.Y. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.J. Clin. Pharmacol.201252797698410.1177/0091270011408611 21593280
     [Google Scholar]
  22. WangH. ShaoF. LiuX. Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control.Br. J. Clin. Pharmacol.201985112547255810.1111/bcp.14076 31332820
     [Google Scholar]
  23. YeZ. ChenP. TanC. Effects of ilaprazole on the steady-state pharmacodynamics of clopidogrel in healthy volunteers: An open-label randomized crossover study.Front. Pharmacol.20221395280410.3389/fphar.2022.952804 36160382
     [Google Scholar]
  24. AnanthathandavanP. NarayanasamyD. Computational drug–drug interaction prediction mediated by CYP450 isoforms of Ilaprazole coadministered with clopidogrel.Future Sci. OA2024101FSO96610.2144/fsoa‑2023‑0277 38817377
     [Google Scholar]
/content/journals/cddt/10.2174/0115701638334244241224062453
Loading
Delineating CYP2C19-mediated Interactions: Network Pharmacology Investigation of Ilaprazole and Clopidogrel versus Conventional Proton Pump Inhibitors
Current Drug Discovery Technologies 22, E15701638334244 (2025); https://doi.org/10.2174/0115701638334244241224062453
/content/journals/cddt/10.2174/0115701638334244241224062453
/content/journals/cddt/10.2174/0115701638334244241224062453
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): clopidogrel; CYP2C19-mediated interactions; ilaprazole; pantoprazole; Pharmacology; proton pump inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test